Movement Disorders – PharmaLive

Phase III Results Set Neurocrine Up for Huntington’s Chorea sNDA

American Academy of Neurology (AAN) Annual Meeting, Brain Diseases, Chorea, Clinical Trials, Dyskinesia, Genetic Brain Disease, Huntington’s Disease, Movement Disorders, R&D, Supplemental New Drug Application (sNDA), Therapeutics

Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).

April 1, 2022/by BioSpace

Capricor places Duchenne drug trial on hold

Clinical Hold, Duchenne Muscular Dystrophy (DMD), FDA/Regulatory, Genetic Disorders, Movement Disorders, Muscle Disorders

Capricor Therapeutics Inc. put on hold a clinical trial of the company’s experimental drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.

December 26, 2018/by Reuters Health

Neurocrine Announces FDA Approval of 80 mg Ingrezza Capsules for the Treatment of Adults with Tardive Dyskinesia

Biotech, FDA, Neurons, Tardive Dyskinesia, VMAT2 Inhibitors

Neurocrine Biosciences Inc. announced today that the U.S. Food and Drug Administration approved an 80-mg Ingrezza (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia.

October 5, 2017/by PR Newswire

FDA Approves Austedo for Tardive Dyskinesia

Approvals, Chorea, FDA, FDA/Regulatory, Gastrointestinal Conditions, Huntington's Disease, Mental Health, Movement Disorders, New Indications, Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

August 30, 2017/by Business Wire

FDA approves movement disorder drug

Approvals, FDA, FDA/Regulatory, Movement Disorders, Shares, Tardive Dyskinesia

The U.S. FDA approved Neurocrine Biosciences Inc.’s drug to treat tardive dyskinesia, an uncontrolled movement side effect of antipsychotic medications.

April 11, 2017/by Reuters Health

Teva Wins FDA Approval for Austedo

Approvals, Chorea, FDA, FDA/Regulatory, Huntington's Disease, Movement Disorders, Potential Blockbusters, Shares, Tardive Dyskinesia, VMAT2 Inhibitors

Teva finally won approval from the U.S. FDA for Austedo, a treatment for chorea associated with Huntington’s disease.

April 4, 2017/by BioSpace